Onesource Specialty Pharma Share Price Today

OneSource Specialty Pharma shareholders approve auditor appointment, resolutions

Shareholders approved B S R & Co LLP as statutory auditors for a 5-year term with 96.23% votes in favour. Special resolution for additional MD remuneration passed with 94.46% support, facing 5.54% opposition. Material related party transactions with Strides Pharma entities approved with 99.99% votes in favour. Re-appointment of Neeraj Sharma as director secured 97.04% shareholder approval.

OneSource Pharma adds RPT details to AGM notice for Sept 23 meeting

OneSource Specialty Pharma issued an addendum to its 19th AGM notice dated July 24, 2026. Additional disclosures relate to RPTs with Strides Pharma Science Limited and its US subsidiary. Audit Committee reviewed CEO/CFO certificates as per Industry Standards for RPTs. The 19th AGM is scheduled for September 23, 2026, via Video Conferencing.

OneSource Specialty Pharma files FY26 BRSR report with zero liquid discharge

OneSource Specialty Pharma filed its FY26 BRSR report disclosing ₹14,204 million standalone turnover. Renewable energy consumption rose to 1,13,219 GJ while non-renewable fuel use dropped significantly. Company achieved zero liquid discharge with no external water release from manufacturing units. Permanent employee turnover declined to 23% from 27% in the prior fiscal year. SGS India provided reasonable assurance on core sustainability indicators.

OneSource Specialty Pharma revises 19th AGM time to 5 pm

OneSource Specialty Pharma reschedules its 19th AGM to 5:00 pm IST. The meeting is held on September 23, 2026, via VC/OAVM. It is the company's second annual general meeting after listing. Electronic notices and annual reports for FY26 are available online.

OneSource Specialty Pharma hosts group investor meet on Sep 3

OneSource Specialty Pharma hosts physical group investor meet on September 3, 2026. Venue is the manufacturing facility in Doddaballapura, Bengaluru Rural District. Discussions will cover business strategy and industry trends using public information. Company confirms no unpublished price-sensitive information will be shared.

OneSource Specialty Pharma Q1FY27 revenue up 37%, EBITDA surges 39%

OneSource Specialty Pharma delivered strong Q1FY27 results with revenue up 37% and EBITDA up 39%, driven by semaglutide commercialization in Canada and India. The company expanded EBITDA margins to 27.5% and adjusted PAT surged 72% to ₹637 million. Management highlighted full capacity utilization, new biologics partnerships with Formycon, and reaffirmed FY28 targets of $400 million revenue and 40% EBITDA margins, supported by upcoming capacity expansions in DDC and injectables.